Prescription medicine
Drospirenone and ethinyl estradiol Brand names: Yasmin, Yaz, Loryna, Syeda, Vestura
Drospirenone and ethinyl estradiol (Yaz) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 15 generic labelers, and pharmacies paid $0.151 per drospirenone-ee 3-0.03 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the drospirenone and ethinyl estradiol FDA label on DailyMed (effective May 29, 2025, Bayer HealthCare Pharmaceuticals Inc.); the NDA 21098 record on Drugs@FDA; every drospirenone and ethinyl estradiol label on DailyMed.
Highlights of the record
FDA label of May 29, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning.
Women over 35 years old who smoke should not use Yaz ( 4 ).
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.
Used for
From the label: indications and usageYaz is a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to:
Prevent pregnancy.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- May 11, 2001 Yasmin, Bayer Hlthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 25 first May 9, 2008; 18 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 16 of which 15 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.151 per tablet Drospirenone-ee 3-0.03 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 44,288 through July 30, 2026
What is drospirenone and ethinyl estradiol used for?
From the label: indications and usageYaz is a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to:
Prevent pregnancy. ( 1.1 )
Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 )
Treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. […]
Conditions named in the indications of drospirenone and ethinyl estradiol's FDA labels, with every medicine labeled for each:
From other drospirenone and ethinyl estradiol labelsBirth control: Oral Contraceptive Yaz ® is indicated for use by females of reproductive potential to prevent pregnancy.
Source: FDA drug label (Yaz), Bayer HealthCare Pharmaceuticals Inc., effective May 29, 2025 (SPL set 065f33e4-b587-4e66-b896-ca9ab7b7c876), via openFDA; the full label on DailyMed
Is there a generic for drospirenone and ethinyl estradiol (Yaz)?
The FDA approved the first generic drospirenone and ethinyl estradiol on May 9, 2008. 25 generic applications are approved; 18 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists drospirenone and ethinyl estradiol from 15 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2001 earliest approval on file
- 2008 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for drospirenone and ethinyl estradiol (Yaz)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.151 per Drospirenone-ee 3-0.03 mg tablet, down 5% from $0.159 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Drospirenone-ee 3-0.03 mg tablet (generic)
- Yasmin 28 tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Drospirenone-ee 3-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Drospirenone-ee 3-0.03 mg tablet | Generic | $0.151 per tablet | $4.53 | -5% |
| Jasmiel 3 mg-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Lo-zumandimine 3 mg-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Loryna 3 mg-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Nikki 3 mg-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Syeda 28 tablet | Generic | $0.151 per tablet | $4.53 | -5% |
| Vestura 3 mg-0.02 mg tablet | Generic | $0.191 per tablet | $5.73 | +23% |
| Zumandimine 3 mg-0.03 mg tablet | Generic | $0.151 per tablet | $4.53 | -5% |
| Yasmin 28 tablet | Brand | $4.40 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $131.91 | -0.2% |
| Yaz 28 tablet | Brand | $5.84 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $175.31 | -0.4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the drospirenone and ethinyl estradiol label say about other medicines?
The drospirenone and ethinyl estradiol label names 34 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | drug interactions | Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. |
| Ascorbic acid | drug interactions | Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. |
| Atorvastatin | drug interactions | Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing EE increase AUC values for EE by approximately 20%. |
| Bosentan | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Carbamazepine | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Clarithromycin | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin … |
| Diltiazem | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin … |
| Enalapril | drug interactions | A drug-drug interaction study of DRSP 3 mg/estradiol (E2) 1 mg versus placebo was performed in 24 mildly hypertensive postmenopausal women taking enalapril maleate 10 mg twice daily. |
| Erythromycin | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin … |
| Estradiol | drug interactions | A drug-drug interaction study of DRSP 3 mg/estradiol (E2) 1 mg versus placebo was performed in 24 mildly hypertensive postmenopausal women taking enalapril maleate 10 mg twice daily. |
| Felbamate | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Fluconazole | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin … |
| Griseofulvin | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Heparin | warnings and precautions | Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. |
Every other medicine the drospirenone and ethinyl estradiol label names
| Medicine named | Section | What the label says |
|---|---|---|
| Itraconazole | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g. … |
| Ketoconazole | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g. … |
| Lamotrigine | drug interactions | COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. |
| Levonorgestrel | warnings and precautions | … a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins. |
| Medroxyprogesterone | warnings and precautions | … norgestimate, norethindrone, levonorgestrel, desogestrel, norgestrel, medroxyprogesterone, or ethynodiol diacetate; Hazard Ratio (HR) (95% CI): HR: 0.9 (0.5-1.6) |
| Midazolam | drug interactions | … weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g. … |
| Norethindrone | warnings and precautions | … Includes low-dose COCs containing the following progestins: norgestimate, norethindrone, levonorgestrel, desogestrel, norgestrel, medroxyprogesterone, or ethynodiol diacetate; … |
| Norgestrel | warnings and precautions | … containing the following progestins: norgestimate, norethindrone, levonorgestrel, desogestrel, norgestrel, medroxyprogesterone, or ethynodiol diacetate; Hazard Ratio (HR) (95% CI): HR: 0.9 (0.5-1.6) |
| Omeprazole | drug interactions | … midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. |
| Oxcarbazepine | drug interactions | … phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Phenytoin | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine … |
| Rifampin | drug interactions | … barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Ritonavir | contraindications | Use of Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug … |
| Simvastatin | drug interactions | Two additional clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4 were each performed in 24 healthy postmenopausal women. |
| Spironolactone | warnings and precautions | … hyperkalemia in high-risk patients, comparable to a 25 mg dose of spironolactone. |
| Theophylline | drug interactions | … substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. |
| Tizanidine | drug interactions | … omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. |
| Topiramate | drug interactions | … carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. |
| Verapamil | drug interactions | … antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma … |
| Voriconazole | drug interactions | Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g. … |
Check drospirenone and ethinyl estradiol against other medicines
Source: FDA drug label (Yaz), Bayer HealthCare Pharmaceuticals Inc., effective May 29, 2025 (SPL set 065f33e4-b587-4e66-b896-ca9ab7b7c876), via openFDA; the full label on DailyMed
What do FAERS reports show for drospirenone and ethinyl estradiol?
The FDA Adverse Event Reporting System holds 44,288 reports that list drospirenone and ethinyl estradiol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 668 are coded as a death and 20,332 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
How does drospirenone and ethinyl estradiol compare with medicines for the same use?
1 side-by-side page set drospirenone and ethinyl estradiol beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Drospirenone and ethinyl estradiol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other